Skip to main content

Table 1 Patient clinical characteristics

From: Identification of SMAD4-mutated pancreatic ductal adenocarcinoma using preoperative contrast-enhanced MRI and clinical characteristics

Characteristics

Non-SMAD4-mutated PDAC (n = 204)

SMAD4-mutated PDAC (n = 224)

P value

Age

64.74 ± 9.27

64.57 ± 9.03

0.850

Sex

   

   Male

115(56.37%)

131(58.48%)

0.659

   Female

89(43.63%)

93(41.52%)

 

BMI

22.69 ± 3.16

22.82 ± 3.26

0.708

Diabetes

  

0.247

   Absence

148(72.55%)

151(67.41%)

 

   Presence

56(27.45%)

73(32.59%)

 

HBP

  

0.647

   Absence

113(55.39%)

129(57.59%)

 

   Presence

91(44.61%)

95(42.41%)

 

CA19-9 (U/mL)

  

0.010

   > 100

94(46.08%)

76(33.93%)

 

   ≤ 100

110(53.92%)

148(66.07%)

 

TBil (µmol/L)

  

0.245

   > 20.4

65(31.86%)

83(37.05%)

 

   ≤ 20.4

139(68.14%)

140(62.5%)

 

Albumin (g/L)

  

0.373

   > 37

169(82.84%)

178(79.46%)

 

   ≤ 37

35(17.16%)

46(20.54%)

 

T stage

  

0.427

   T1

62(30.39%)

58(25.89%)

 

   T2

109(53.43%)

136(60.71%)

 

   T3

32(15.69%)

28(12.5%)

 

   T4

4 (0.49%)

1 (0.9%)

 

N stage

  

0.527

   N0

120(58.82%)

122(54.46%)

 

   N1

73(35.78%)

85(37.95%)

 

   N2

11(5.39%)

17(7.59%)

 

Resection margin

  

0.180

   R0

199(97.55%)

213(95.09%)

 

   R1

5(2.45%)

11(4.91%)

 
  1. PDAC = pancreatic ductal adenocarcinoma, BMI = body mass index, HBP = high blood pressure; TBil = total bilirubin, CA 19 − 9 = cancer antigen 19 − 9